{"id":391142,"date":"2016-05-06T00:00:00","date_gmt":"2016-05-06T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/unneim0003-2016-biopharma-chronic-obstructive-pulmonary-disease-unmet-need-us-eu-2016\/"},"modified":"2026-04-17T23:42:21","modified_gmt":"2026-04-17T23:42:21","slug":"unneim0003-2016-biopharma-chronic-obstructive-pulmonary-disease-unmet-need-us-eu-2016","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/unneim0003-2016-biopharma-chronic-obstructive-pulmonary-disease-unmet-need-us-eu-2016\/","title":{"rendered":"Chronic Obstructive Pulmonary Disease | Unmet Need | US\/EU | 2016"},"content":{"rendered":"<p>The chronic obstructive pulmonary disease (COPD) market is becoming increasingly crowded, but significant unmet need remains due to the lack of a disease-modifying therapy. In recent years, several new combination therapies have been approved for the treatment of COPD, further increasing the competition. Although these new therapies perform well on a variety of clinical end points, most offer only incremental improvements, and none have yet demonstrated a statistically significant decrease in all-cause mortality. Owing to the high level of unmet need in COPD, significant clinical and commercial opportunity remains for therapies that can provide a decrease in all-cause mortality, number of exacerbations, or improvement on several clinically important end points, including FEV1 and frequency of exacerbations, compared with current standards of care.<\/p>\n","protected":false},"template":"","class_list":["post-391142","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-chronic-obstructive-pulmonary-disease","biopharma-product-unmet-need","biopharma-geography-us","biopharma-date-858"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/391142","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":1,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/391142\/revisions"}],"predecessor-version":[{"id":394265,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/391142\/revisions\/394265"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=391142"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}